Abstract：
Cisplatin chemoradiotherapy (CRT) is the established standard of care for managing locally advanced human papillomavirus-positive head/neck carcinoma. The typically young patients may suffer serious and long-time side effects caused by the treatment, such as dysphagia, and hearing loss. Thus, ensuring a satisfactory post-treatment quality of life is paramount. One potential replacing approach to the classical CRT involves the combination of standard-dose radiotherapy and radiosensitizers such as noble metal nanoparticles (NPs). However, several concerns about size, shape, and biocompatibility limit the translation of metal nanomaterials to the clinical practice. Here, it is demonstrated that a new model of nonpersistent gold nanoarchitectures containing cisplatin (NAs-Cluster-CisPt) generates, in combination with radiotherapy, a significant in vivo tumor-reducing effect compared to the standard CRT, achieving a complete tumor clearance in 25% of the immunocompetent models that persist for 60 days. These findings, together with the negligible amount of metals recognized in the excretory organs, highlight that the concurrent administration of NAs-Cluster-CisPt and radiotherapy has the potential to overcome some clinical limitations associated to NP-based approaches while enhancing the treatment outcome with respect to standard CRT. Overall, despite further mechanistic investigations being essential, these data support the exploiting of nonpersistent metal-nanomaterial-mediated approaches for oral cancer management.
摘要：
顺铂放化疗（CRT）是控制HPV头颈部癌的既定护理标准。典型的年轻患者可能遭受治疗引起的严重和长期的副作用，比如吞咽困难,和听力损失。因此，确保满意的治疗后生活质量至关重要。经典CRT的一种潜在替代方法涉及标准剂量放射治疗和放射增敏剂如贵金属纳米颗粒(NP)的组合。然而,关于尺寸的几个问题，形状和生物相容性限制了金属纳米材料在临床实践中的应用。这里,我们证明了含有顺铂（NAs-Cluster-CisPt）的非持久性金纳米结构的新模型，结合放射治疗，与标准CRT相比，体内显着减少肿瘤的作用，在25％的持续60天的免疫活性模型中实现了完全的肿瘤清除。这些发现,连同在排泄器官中识别的可忽略不计的金属，强调NAs-Cluster-CisPt和放疗的同时给药有可能克服与基于NP的方法相关的一些临床限制，同时提高标准CRT的治疗结果。总的来说,尽管进一步的机械调查至关重要，我们的数据支持利用非持久性金属纳米材料介导的口腔癌治疗方法.本文受版权保护。保留所有权利。
